Full text is available at the source.
Abstract
A total of 1,034 participants were included in 21 randomized controlled trials of psychedelic-assisted therapies.
- Gender was reported in 100% of the studies, while race or ethnicity was reported in 76%.
- Socioeconomic status was reported sometimes (57%), but sexual orientation (9.5%) and immigration status (4.8%) were rarely noted.
- No studies reported on gender identity.
- Black/African-American participants (2.2%) and Hispanic/Latino participants (7.2%) were significantly underrepresented compared to their population proportions.
- MDMA trials included more diverse participant samples than psilocybin trials.
- Analyses of treatment effects based on demographic variables were virtually nonexistent.
Simplified